Navigation Links
Acumen Pharmaceuticals Regains Worldwide Rights to Anti-ADDL Antibody Therapeutics and Diagnostics for Alzheimer's Disease From Merck
Date:12/21/2011

SAN FRANCISCO, Dec. 21, 2011 /PRNewswire/ -- Acumen Pharmaceuticals announces today the termination by Merck Sharp & Dohme Corp., (formerly Merck & Co., Inc.) of a 2003 agreement, amended in 2006, under which Acumen granted Merck exclusive worldwide rights to develop and commercialize anti-ADDL antibody therapeutics and diagnostics for Alzheimer's disease.

Merck's decision to discontinue this anti-ADDL Alzheimer's program and terminate the Merck-Acumen license agreement was based on internal strategic priorities. Under the termination provisions of the agreement, Acumen regains rights licensed to Merck, and also receives certain rights to patent applications and know how generated during the term of the Agreement. Anti-ADDL antibodies have high selectivity for soluble amyloid beta oligomers versus monomeric amyloid beta peptides or insoluble amyloid beta aggregates. Acumen believes this selectivity will favorably differentiate Acumen anti- ADDL immunotherapies compared to amyloid beta immunotherapies currently in late stage clinical testing.

"Acumen is very pleased to regain worldwide rights for the development and commercialization of anti-ADDL antibody therapeutics and diagnostics," stated Grant Krafft, Acumen's Chairman and Chief Science Adviser.

Acumen's Board of Directors also announces the appointment of Franz Hefti, Ph.D. as Acumen's President and CEO. Dr. Hefti has served as a Director of Acumen since 2008 and has a distinguished record in drug development and biotechnology ventures. Dr. Hefti served as Chief Science Officer for Avid Radiopharmaceuticals, which Eli Lilly & Co. acquired in 2010 for its Alzheimer's imaging product, Amyvid™. Prior to Avid, Dr. Hefti was Executive Vice President of Drug Development for Rinat Neuroscience Corporation where he led preclinical and clinical drug development efforts for three antibody drug candidates. The success of these programs led to Pfizer's 2006 acquisition of Rinat.
'/>"/>

SOURCE Acumen Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Synergy Pharmaceuticals, Inc. Files Suit Against Ironwood Pharmaceuticals, Inc. and its Chief Scientific Officer and Senior VP of R&D, Dr. Mark G. Currie
2. Questcor Pharmaceuticals to Present at the Oppenheimer Healthcare Conference on December 13, 2011
3. TetraLogic Pharmaceuticals Announces Initiation of a Phase 1/2 Clinical Trial of TL32711 in Patients with Acute Myelogenous Leukemia (AML)
4. Convergence Pharmaceuticals Initiates Phase I Multiple Ascending Dose Study for CNV2197944
5. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
6. Access Pharmaceuticals Signs Agreement for CobaCyte® and CobOral® in RNAi Therapeutic Delivery
7. Radient Pharmaceuticals Announces Proxy Resolutions Approved at Special Meeting of Stockholders
8. Cumberland Pharmaceuticals Reports Third Quarter 2011 Financial Results
9. Optimer Pharmaceuticals Reports Third Quarter 2011 Financial Results
10. Cadence Pharmaceuticals CEO Ted Schroeder to Present at the Credit Suisse Healthcare Conference on November 9, 2011
11. Optimer Pharmaceuticals to Present at 20th Annual Credit Suisse Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... -- According to a new market research ... Thawing Equipment, Alarms), by Biospecimen (Human Tissue, Stem Cells, ... - Global Forecast to 2020", published by MarketsandMarkets, the ... Million by 2020 from USD 2,150.48 Million in 2015, ... 2020. Browse 74 Tables and 95 ...
(Date:8/28/2015)... ... , ... Since the initial launch of FireflySci Inc. (FFS) in early 2015, the company continues ... Images such as the Fonz in a lab coat and Large Marge have been posted ... field. , FireflySci is proud to be the only cuvette manufacturer is the ...
(Date:8/27/2015)... Fla. , Aug. 27, 2015 The ... that a patient,s eyes—and life—were saved by doctors at ... , working with NNFF, NovaBay Pharmaceuticals and Dr. ... Care Center at Seton Medical Center in ... successful treatment used a breakthrough approach, pioneered by Dr. ...
(Date:8/27/2015)... ... August 27, 2015 , ... Inc. Magazine released its annual ... Solutions as number 1,361 in growth for the three years through 2014. Being named ... fastest-growing privately held organizations in the country. , “We are thrilled to make ...
Breaking Biology Technology:Biopreservation Market Worth 3,731.03 Million USD by 2020 2Biopreservation Market Worth 3,731.03 Million USD by 2020 3Biopreservation Market Worth 3,731.03 Million USD by 2020 4Biopreservation Market Worth 3,731.03 Million USD by 2020 5Cuvette Manufacturer FireflySci Launches Back to School Deals with Complimentary Shipping On All Orders 2Patient's Life and Eyes Saved from Gruesome Flesh-Eating Infection Consuming Her Face 2Patient's Life and Eyes Saved from Gruesome Flesh-Eating Infection Consuming Her Face 3iLab Solutions Named to 2015 Inc. 5000 List 2iLab Solutions Named to 2015 Inc. 5000 List 3
... Convergent Procedure, a novel approach to treat atrial ... nContact Surgical, Inc. (nContact), was highlighted at the ... Association for Cardio-Thoracic Surgery) Annual Meeting in Geneva, ... 2010 Techno-College Programme to receive an update on ...
... Nev., Sept. 10 PDL BioPharma, Inc. (PDL) (Nasdaq: ... will redeem all of the Company,s outstanding 2.75% Convertible Subordinated ... the 2023 Notes have been provided notice of the redemption ... 2023 Note holders who elect to convert their 2023 Notes ...
... ... if (typeof(lpUnit)==,undefined,) var lpUnit=,PRN,; ... var shortURL = ""; BitlyCB.alertResponse = function(data) { ... the first one. for (var r in data.results) { first_result = data.results[r]; break; } for (var key ...
Cached Biology Technology:The Convergent Procedure for the Treatment of Chronic Atrial Fibrillation Highlighted at EACTS Annual Meeting in Geneva 2PDL BioPharma Provides Clarification Regarding Redemption of Its 2.75% Convertible Subordinated Notes 2Nucletron Spotlights Innovations During ESTRO29 2Nucletron Spotlights Innovations During ESTRO29 3Nucletron Spotlights Innovations During ESTRO29 4Nucletron Spotlights Innovations During ESTRO29 5Nucletron Spotlights Innovations During ESTRO29 6Nucletron Spotlights Innovations During ESTRO29 7
(Date:8/6/2015)... CITY, Calif. , Aug. 6, 2015 /PRNewswire/ ... Valley) will visit Crossmatch ™ to learn ... networks and protect data. Crossmatch is a world ... whose technologies and expertise are helping federal agencies ... efficiency and security.   "The vast ...
(Date:8/5/2015)... 2015 Transparency Market Research has ... - Global Industry Analysis, Size, Share, Growth, Trends and ... recognition is forecast to reach US$ 2,671.8 Mn by ... surveillance systems by civil and government agencies. This is ... terrorist activities across the globe that would elevate the ...
(Date:8/3/2015)... JOSE, Calif. , Aug. 3, 2015 ... of human interface solutions, today announced that members of ... community at the Pacific Crest Global Technology Leadership Forum ... Time. The conference will be held at the Sonnenalp ... The presentation may include forward-looking information. An ...
Breaking Biology News(10 mins):Rep. Honda to Visit Crossmatch in Redwood City 2Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 2Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 3Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 4Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 5Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 6
... University of Liverpool has found that greater consideration ... infectious disease model would improve its effectiveness/usefulness and ... central role in planning for outbreaks of human ... progress and guiding and informing policy responses. ...
...   Arcturus Therapeutics, Inc. , an industry leader in RNAi technologies ... secured $5 million in a Series A funding round led by ... , Japan and the United ... The Series A funding, which comprised more than 90% of ...
... a biological quirk that promises to provide researchers with ... X syndrome, scientists at the University of Massachusetts Medical ... important for messenger RNA (mRNA) translation in neurons restores ... model of a prevalent human neurological disease. These results, ...
Cached Biology News:Study explores the role of uncertainty in infectious disease modelling 2Arcturus Therapeutics Raises $5 Million in Series A Funding to Maintain its Momentum in Nominating Lead Clinical Candidate in 2014 2Arcturus Therapeutics Raises $5 Million in Series A Funding to Maintain its Momentum in Nominating Lead Clinical Candidate in 2014 32 genetic wrongs make a biochemical right 22 genetic wrongs make a biochemical right 32 genetic wrongs make a biochemical right 4
... is ideal for the ... (1D electrophoresis, 2D electrophoresis, ... Pharmacokinetics & Toxicology (whole ... chromatography); Physical and Material ...
Fujifilm BAS-1800II provides the ideal configuration for a low-cost imager that requires only a small amount of space in the laboratory. The small imager for accurate high-throughput screening...
lid holder -see Blotters (Semi-Dry) for more info...
... QPlate is the consumable ... 16 contains 16 individually controlled ... contains a sophisticated liquid flow ... fast and precise solution and ...
Biology Products: